Approximately 80% of patients with primary sclerosing cholangitis (PSC) of Northern European origin have inflammatory bowel disease (IBD), the majority ulcerative colitis (UC). An inherent problem in interpreting positive findings in genetic association studies of PSC is thus to distinguish between factors associated with hepatobiliary versus intestinal pathology. We aimed to clarify to what extent human leukocyte antigen (HLA) class II associations in UC patients with and without PSC differ. Highresolution DRB1 and DQB1 typing was performed in 365 Scandinavian PSC patients, an independent cohort of 330 Norwegian UC patients and 368 healthy controls. HLA associations found in PSC were mostly distinct from those seen in UC, and no significant differences were noted between PSC patients with concurrent UC and PSC patients without IBD. This suggests different HLA associated genetic susceptibility to PSC and UC, and supports notions that UC in PSC may represent a distinct UC phenotype.
Introduction
Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colonic mucosa. 1 Although several clinical and pathological features of UC resemble Crohn's disease, there are major differences between these two inflammatory bowel disease (IBD) phenotypes. 2 The presence of genetic risk factors for UC can be demonstrated, however, the exact susceptibility genes involved have so far proven more difficult to identify than in Crohn's disease. 3 Extra-intestinal inflammatory manifestations are common in IBD, 2 and primary sclerosing cholangitis (PSC) is the single most frequent hepatobiliary lesion in UC and is diagnosed in 2-4.4% of the cases. 4 PSC is defined by progressive stricturing of the intraand extrahepatic bile ducts owing to inflammation and fibrosis. 5 No effective medical treatment is currently available 6 and PSC is the major indication for liver transplantation in the Nordic countries. 7 The etiology of PSC remains largely unknown, although complex genetic factors most likely play an important role in the pathogenesis. 8 Approximately 80% of PSC patients of northern European origin have concurrent IBD, the majority UC. 9 An inherent problem in interpreting positive findings in genetic association studies of PSC is thus to distinguish between factors associated with intestinal versus biliary pathology.
In both UC and PSC, disease associations have been demonstrated for several genetic variants within the human leukocyte antigen (HLA) complex on chromosome 6p21. 10, 11 Most consistent in UC are the positive associations with the DRB1*0103 and DRB1*1502 alleles, and a negative association with DRB1*0401. 12, 13 In PSC, the most prominent positive HLA associations are with the HLA-A*01-C*07-B*08-DRB1*0301-DQB1*0201 and DRB1*1301-DQB1*0603 haplotypes, and the negative associations with DRB1*04 alleles. 14, 15 In individuals negative for the DRB1*0301 and DRB1*1301 alleles, an association is found with the DRB1*1501-DQB1*0602 haplotype. 14, 15 As a protective effect of DRB1*04 alleles has been reported in both UC and PSC, it has been speculated that this observation in PSC may be owing to concurrent UC. 15 Furthermore, an increased frequency of the DRB1*0301 allele has been reported in UC patients with extensive colitis, 16 a characteristic feature of UC in PSC. 17 We aimed to clarify to what extent HLA class II associations in UC patients with and without PSC differ, by studying the following four phenotypes in parallel: PSC with UC, PSC without IBD, UC without liver disease and extensive colitis without liver disease. Two large cohorts of clinically well-characterized UC (Table 1) and PSC (Table 2 ) patients of the same ethnicity were included. Because the HLA associations in UC are observed mainly for DRB1 and DQB1 alleles, we limited our analyses to encompass these loci. 12 
Results and discussion
Allele frequencies for DRB1 or DQB1 alleles, previously shown to be associated with PSC or UC in two or more independent reports, are shown in Table 3 . 12, 14, 15 In brief, this table demonstrates that strong HLA associations detected in PSC do not seem to arise because of similar associations in UC. For PSC with UC, HLA haplotypes, representing either genuine HLA effects or risk variants in neighboring genes, seem to play an important and distinct role. HLA associations in UC without liver disease seem to be of lesser impact and appear mostly distinct from those seen in PSC. This suggests different patterns of HLA-associated genetic susceptibility to UC in PSC and UC without liver disease.
Considering UC patients without liver disease, no statistically significant associations were observed with previously UC associated DRB1 or DQB1 alleles 12 in the present cohort (Table 3 and Table 4 ). In particular, no overall effects of DRB1*04 alleles on UC susceptibility was evident (OR ¼ 0.82, 95% CI (0.63, 1.1), P ¼ 0.14), whereas these alleles conferred strong protection against PSC (OR ¼ 0.28, 95% CI (0.20, 0.39), P ¼ 10
À13
). Furthermore, the frequency of the DRB1*0401 allele, specifically reported to confer protection against UC, 18 was almost identical in UC patients as compared with healthy controls whereas decreased among patients with PSC (Table 4 ). Earlier studies of the HLA class II genes in UC have focused on phenotypic and not allelic associations. 12, 18 However, even the frequency of the DRB1*0401 phenotype was similar in patients with UC as compared with healthy controls (23.0 versus 23.4%, P ¼ 0.90), whereas decreased among patients with PSC (9.6 versus 23.4%, P ¼ 10
À6
). The only significant HLA class II association detected in our Scandinavian UC population, was a previously unreported decrease in the frequency of the DRB1*0404 allele in the patients as compared with the healthy controls ( Table 4 , P corrected ¼ 0.03; Bonferroni correction factor of 32 according to the number of DRB1 alleles). This allele was even more reduced among PSC patients when compared with UC patients without liver disease (P ¼ 0.05).
Considering PSC patients with concurrent UC, we found no significant differences in the DRB1 and DQB1 allele frequencies among these patients as compared with PSC patients without IBD (Table 3) . Two trends nevertheless require mentioning. First, although no difference in the overall DRB1*04 allele frequency was noted (Table 3 , P ¼ 0.3), at a higher resolution level a nonsignificant reduction in DRB1*0401 alleles in PSC patients with concurrent UC as compared with PSC patients without IBD became evident (Table 4 , P ¼ 0.09). Second, the increase in DRB1*1501 allele frequency seen among DRB1*0301 and DRB1*1301 negative patients with PSC, was slightly more pronounced in patients with UC than in patients without IBD (Table 3 , P ¼ 0.12). The present population of PSC patients is the largest reported to date. However, owing to the low number of PSC patients without IBD (n ¼ 73) and the low frequencies of the DRB1*0401 allele in patients both with and without UC, it cannot be excluded that failure to achieve statistical significance for the DRB1*0401 comparison results from lack of statistical power (post hoc estimated at 0.27 for DRB1*0401 and at 0.88 for DRB1*1501). The possibility should be kept open that these haplotypes may harbor variants of importance for the UC phenotype in PSC.
Among PSC patients with UC, a high frequency of extensive colitis has been noted (490%). 17 As shown in Table 3 , even for this subphenotype of UC patients without liver disease, no significant associations were detected for PSC associated DRB1 and DQB1 alleles. This indicates that these similar UC phenotypes may arise via different pathogenetic mechanisms. 17 Clinical data and characteristic features of UC in PSC, like the increased risk of colorectal cancer and mild-clinical course, support this view. 17, 19 Another possibility is that genetic risk The patients were recruited through a population based incidence study (the Inflammatory Bowel in Southeastern Norway (IBSEN) study). 21 The 11 patients with evidence for liver disease at 5-years follow-up were excluded from all statistical analyses. HLA in PSC and UC TH Karlsen et al factors shared by UC in PSC and extensive UC in general localizes to genetic regions other than the HLA complex. 20 Previous studies of HLA associations in UC have also emphasized the need to take disease heterogeneity into account. 10 In particular, the DRB1*0103 allele has been associated with extensive and severe disease. 18 In the present population, no significant association was detected in UC patients with extensive colitis as compared with healthy controls (OR 1.7, 95% CI (0.6, 4.5), P ¼ 0.32), however, a slight increase among patients with severe disease (defined as the need for colectomy) (OR ¼ 4.4, 95% CI (1.2, 16.5), P ¼ 0.03) was evident.
Although our UC population was equally sized as in previous HLA studies of European UC populations, 18 pre hoc power estimates using published phenotype frequencies and relative risks, 18 demonstrated that for rare DRB1 phenotypes, statistical power for replication was suboptimal (0.6 for DRB1*0103 and 0.3 for DRB1*1502). However, lack of statistical power is less likely to serve as an explanation for the failure to replicate the previously noted DRB1*0401 phenotype association (pre hoc power estimated at 0.8), 12, 18 and other explanations need consideration. Several lines of evidence point to the presence of genetic heterogeneity with regard to IBD susceptibility variants even within the European population. 3 Our findings suggest that this may also apply to HLA associations in UC.
In conclusion, the HLA-associated susceptibility to UC with and without PSC differs. The present study adds further evidence to the notion that the genetic susceptibility to PSC and the UC phenotype in PSC needs to be considered on different premises from that of UC in general. 20 
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